Medical cannabis significantly improved severe, treatment-resistant OCD in a 22-year-old man

A 22-year-old male with severe OCD since childhood, previously resistant to standard treatments, showed marked improvement in OCD symptoms and depression with medicinal cannabis, resulting in considerable quality of life improvement. The literature review found only 2 prior case reports of successful THC treatment for OCD, one small trial of nabilone plus exposure therapy, and supporting evidence from Tourette syndrome patients with comorbid obsessive-compulsive behavior.

Case report with literature review of cannabinoid effects in animal models and patients with OCD, proposing a cannabinoid hypothesis of OCD pathophysiology.

OCD affects 2-3% of the population and is among the most treatment-resistant psychiatric conditions. The endocannabinoid system involvement opens an entirely new therapeutic pathway beyond the serotonergic model that has dominated OCD treatment.

The proposed cannabinoid hypothesis of OCD suggests the endocannabinoid system modulates the compulsive behaviors and intrusive thoughts characteristic of OCD. If confirmed, this would expand treatment options for a condition where current medications help only 40-60% of patients.

Single case report; cannot establish causation; placebo/expectancy effects possible; patient may have had comorbidities affecting response; only 3 total OCD case reports in the literature; no standardized outcome measures reported in abstract.